Molecular Breast Imaging: Effect of Menstrual Cycle, Hormone Therapy, and Tamoxifen on Tc-99m Sestamibi Uptake in the Breast.
Arm 1
Inclusion Criteria:
- age 35-45
- have regular menstrual cycles as defined by having menstrual cycle length of 25-31
days, with menstrual flow of 2-7 days, and no intermenstrual spotting or bleeding.
- have had a negative screening mammogram within one year prior to the MBI studies that
is available for comparison.
Exclusion Criteria:
- currently using any exogenous hormones (e.g., hormonal contraceptives, sex steroid
hormones) or any estrogen receptor modulating drugs (e.g., tamoxifen, raloxifene) or
any aromatase inhibitors
- have a personal history of any cancer, except non-melanomatous skin cancer
- unable to understand and sign the consent form
- pregnant or lactating
- physically unable to sit upright and still for 30 minutes
Arm 2
Inclusion Criteria:
- scheduled to begin one of the following regimens of HT:
- Any dosage of any formulation of systemic estrogen therapy in the setting of a prior
hysterectomy
- Any dosage of continuous estrogen plus monthly, cyclic progesterone therapy where the
progesterone therapy is the oral, micronized formulation
- had a negative screening mammogram within one year prior to the MBI studies that is
available for comparison.
Exclusion Criteria:
- have a personal history of any cancer, except non-melanomatous skin cancer
- unable to understand and sign the consent form
- pregnant or lactating
- physically unable to sit upright and still for 30 minutes
Arm 3
Inclusion Criteria:
- scheduled to begin treatment with tamoxifen Or are currently being treated with
tamoxifen (for > 1 month) and have had an MBI scan performed prior to its initiation
- have had or will have the following test performed at Mayo Clinic: #87966, Cytochrome
P450 2D6 genotyping for Tamoxifen Hormonal Therapy
- have had a screening or diagnostic mammogram within one year of the MBI studies that
is available for comparison.
Exclusion Criteria:
- are using or have used any exogenous hormones (e.g., hormonal contraceptives, sex
steroid hormones), any estrogen receptor modulating drugs other than tamoxifen, or
any aromatase inhibitors from the time of 1 month prior to the first MBI until
completion of the second MBI.
- have been treated or will be undergoing treatment with systemic chemotherapy or
external radiation beam therapy to the breast from the time of 6 months prior to the
first MBI until the completion of the second MBI.
- unable to understand and sign the consent form
- pregnant or lactating
- physically unable to sit upright and still for 30 minutes